No causal relationship between transdermal scopolamine and seizures: methodologic lessons for pharmacoepidemiology

Area of Science:

• Pharmacoepidemiology
• Drug Safety
• Retrospective Cohort Studies

Background:

• Case reports suggested a potential link between transdermal scopolamine and seizures.
• This prompted an investigation into the drug's safety profile regarding seizure risk.

Purpose of the Study:

• To investigate the association between transdermal scopolamine use and the subsequent development of seizures.
• To evaluate the reliability of computerized claims data versus primary medical records in pharmacoepidemiologic studies.

Main Methods:

• A retrospective cohort study using computerized Medicaid claims data.
• Comparison of patients using transdermal scopolamine with those using other medications (diphenhydramine, meclizine, prochlorperazine, promethazine).
• Validation of initial findings by reviewing primary medical records.

Main Results:

• Initial claims data indicated a four-fold increased risk of seizures associated with transdermal scopolamine.
• Primary medical record review did not support this association.
• Seizures in the transdermal scopolamine group were either pre-existing or miscoded diagnoses (e.g., 'dizziness, rule out seizures').

Conclusions:

• The study found no evidence to confirm an association between transdermal scopolamine use and seizures.
• The initial finding was likely an artifact of coding practices for 'rule out' diagnoses.
• Emphasizes the critical importance of primary medical records for accurate pharmacoepidemiologic research and drug safety assessment.